Tiziana Life Sciences Ltd(TLSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.16 | Insider Own | 49.02% | Shs Outstand | 120.5M | Perf Week | -1.49% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | -7.38% | Insider Trans | 1.6% | Shs Float | 65.4M | Perf Month | -3.03% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | - | Inst Own | 1.89% | Short Float | 2.6% | Perf Quarter | -15.04% |
| Income | -0.02B | P/S | - | EPS this Y | -7.7% | Inst Trans | -12.81% | Short Ratio | 2.95 | Perf Half Y | -23.81% |
| Sales | 0.00B | P/B | 2232.56 | EPS next 5Y | -5.55% | ROA | -161.82% | Short Interest | 1.70M | Perf YTD | -35.57% |
| Book/sh | 0 | P/C | 30.72 | EPS past 3/5Y | -0.89% -0.19% | ROE | -924.32% | 52W High | -59.15% ($2.35) | Perf Year | -46.37% |
| Cash/sh | 0.03 | P/FCF | - | Sales past 3/5Y | - | ROIC | -6444.41% | 52W Low | 10.82% ($0.87) | Perf 3Y | 26.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -40.11% | Gross Margin | - | Volatility(W/M) | 7.7% 9.29% | Perf 5Y | -49.47% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.76 | EPS Q/Q | -62.78% | Profit Margin | - | RSI (14) | 41.6 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.76 | Sales Q/Q | - | SMA20 | -8.32% ($1.05) | Beta | 0.47 | Target Price | $8.03 |
| Payout | - | Debt/Eq | 9.2 | Earnings | 2026/06/18 | SMA50 | -9.32% ($1.06) | Rel Volume | 0.47 | Prev Close | $0.96 |
| Employees | 10 | LT Debt/Eq | 4.6 | EPS/Sales Surpr. | -21.93% - | SMA200 | -27.23% ($1.32) | Avg Volume(3M) | 0.58M | Price | $0.96 |
| IPO | 2018/11/20 | Option/Short | Yes/Yes | Trades | 667 | Volume | 272,920 | Change | -0.41% |
Company
TLSA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A clinical-stage immunotherapy developer focused on an intranasal antibody therapy platform, advancing drug candidates for central nervous system diseases such as multiple sclerosis and Alzheimer's. With no commercialized products yet, the company generates no revenue, and as an early-stage biotech, its stock price is heavily influenced by clinical trial results and fundraising activities.
Over the past 1 year, on the lower side
59% below its 1-year high.
TLSA has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -7.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +26.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 1.9%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $123M.
TLSA $123M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is TLSA?
TLSA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TLSA?
The market cap of TLSA is approximately $123M, ranking 4,436 within its sector.
What is the 52-week high and low for TLSA?
TLSA has recorded a 52-week high of $2.35 and a low of $0.87.
